| DESCRIPTION | - Pharmaceutical Research, (19860000), vol. 3, no. 6, page 318 |
| DESCRIPTION | - SELLESETH, D.W. et al., Antimicrobial Agents and Chemotherapy, (20030000), vol. 47, pages 1468 - 71 |
| EXAMINATION | - Anon., "Dolutegravir", Chemical Abstracts Regist, Chemical Abstracts Service, (20080922), Database accession no. 1051375-16-6 |
| EXAMINATION | - GALIZZI NADIA ET AL, "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 3, doi:10.1016/J.IJANTIMICAG.2020.105893, ISSN 0924-8579, (20200109), (20200109), XP086083636 |
| EXAMINATION | - VAN WYK JEAN ET AL, "Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study", CLINICAL INFECTIOUS DISEASES, US, (20200106), vol. 71, no. 8, doi:10.1093/cid/ciz1243, ISSN 1058-4838, pages 1920 - 1929, XP093056160 |
| EXAMINATION | - LASKEY SARAH B. ET AL, "Quantitative evaluation of the antiretroviral efficacy of dolutegravir", JCI INSIGHT, (20161117), vol. 1, no. 19, doi:10.1172/jci.insight.90033, XP093056166 |
| EXAMINATION | - CAHN PEDRO ET AL, "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", THE LANCET, (20181109), vol. 393, doi:dx.doi.org/10.1016/ S0140-6736(18)32462-0, pages 143 - 155, XP093056157 |
| OPPOSITION | - Anonymous, "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects", Internet Archive Wayback Machine, (20090904), Internet Archive Wayback Machine, URL: https://web.archive.org/web/20090904062433/http://clinicaltrials.gov/ct2/show/NCT00951015, (20190619), XP055598041 |
| OPPOSITION | - Anonymous, "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS : Epivir 150 mg film-coated tablets , Epivir 300 mg film-coated tablets ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, (20060728), pages 1 - 77, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/epivir-epar-product-information_en.pdf, XP093215065 |
| OPPOSITION | - Anonymous, "Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release", Conference Reports for NATAP, (20090701), Conference Reports for NATAP , URL: http://www.natap.org/2009/IAS/IAS_42.htm, (20190118), XP055544606 |
| OPPOSITION | - Anonymous, "Archive History for NCT00951015 / A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (ING112276)", (20100121), URL: https://clinicaltrials.gov/ct2/history/NCT00951015?A=9&B=9&C=merged#StudyPageTop, (20190627), XP055600260 |
| OPPOSITION | - Anonymous, "Drug Data Report 2010", Drug Data Report, Thomson Reuters, (20101001), vol. 32, no. 9, pages 893 - 895, XP055280507 |
| OPPOSITION | - Anonymous, "EPIVIR Summary of Product Characteristics", EPIVIR Summary of Product Characteristics, European Medicines Agency, (19950101), pages 1 - 44, EPIVIR Summary of Product Characteristics, XP093216539 |
| OPPOSITION | - Anonymous, "EPIVIR® Tablets (lamivudine tablets), EPIVIR® Oral Solution (lamivudine oral solution)", PRESCRIBING INFORMATION, (20061001), pages 1 - 24, XP093230923 |
| OPPOSITION | - Anonymous, "EPZICOM (abacavir sulfate and lamivudine) Tablets, for oral use", Prescribing information, (20120301), pages 1 - 32, XP055600307 |
| OPPOSITION | - Anonymous, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents", Office of AIDS Research Advisory Council (OARAC), (20091201), Office of AIDS Research Advisory Council (OARAC), (20160525), XP055275315 |
| OPPOSITION | - Anonymous, "Highlights of prescribing information for EPIVIR", FDA, (20170901), XP055816986 |
| OPPOSITION | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION VITEKTA ® (elvitegravir) tablets, for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION, FDA, (20140901), pages 1 - 26, HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf, XP093217727 |
| OPPOSITION | - Anonymous, "ISENTRESS (raltegravir) Tablets: HIGHLIGHTS OF PRESCRIBING INFORMATION", Patient Information Leaflet / HIGHLIGHTS OF PRESCRIBING INFORMATION, (20090701), XP055600305 |
| OPPOSITION | - Anonymous, "ISENTRESS (raltegravir) Tablets", Patient Information Leaflet, (20090701), XP055600305 |
| OPPOSITION | - Anonymous, "Kivexa : EPAR - Scientific Discussion", Kivexa : EPAR - Scientific Discussion, European Medicines Agency, (20040101), pages 1 - 29, Kivexa : EPAR - Scientific Discussion, URL: https://www.ema.europa.eu/en/documents/scientific-discussion/kivexa-epar-scientific-discussion_en.pdf, XP093214439 |
| OPPOSITION | - Anonymous, "PRODUCT MONOGRAPH ISENTRESS ™ raltegravir 400 mg film coated tablets (as raltegravir potassium) ", PRODUCT MONOGRAPH, MERCK FROSST CANADA LTD, (20071122), pages 1 - 22, PRODUCT MONOGRAPH, URL: https://web.archive.org/web/20080706020226/http://www.merckfrosst.com/assets/en/pdf/products/ci/ISENTRESS_1106-a_11_07_CI-E.pdf, XP093215129 |
| OPPOSITION | - Anonymous, "Rapid advice Antiretroviral therapy for HIV infection in adults and adolescents", WHO Rapid advice, WHO, ISBN 978-92-4-159895-8, (20091101), pages 1 - 28, WHO Rapid advice, URL: https://iris.who.int/handle/10665/107280, XP093215570 |
| OPPOSITION | - Anonymous, "Tivicay® (Dolutegravir sodium) ", Summary of Product Characteristics, European Medicines Agency, (20180921), pages 1 - 102, Summary of Product Characteristics, URL: https://www.ema.europa.eu/en/documents/product-information/tivicay-epar-product-information_en.pdf, XP093217720 |
| OPPOSITION | - Anonymous, "WHO Model List of Essential Medicines", EML 16, 16th list, (20090301), pages 1 - 39, XP055600280 |
| OPPOSITION | - Booss And Tselis, "Viral Vaccines and Antiviral Therapy", Encyclopedia of the Neurological Sciences, (20030101), pages 1 - 13, XP093230920 |
| OPPOSITION | - Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Hiroshi Yoshida, Edward P. Garvey, William R. Spreen, Mark R. Underwood, Akihiko Sato, Tomokazu Yoshinaga, Tamio Fujiwara, "The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile", 17th CROI, Conference on Retroviruses and Opportunistic Infections, San Francisco CA, San Francisco CA , (20100216), pages 1 - 6, XP055275444 |
| OPPOSITION | - B Young, T Vanig, E DeJesus, T Hawkins, M St. Clair, L Yau, B Ha, "A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects", EACS 12th AIDS Conference; European AIDS Conference, Cologne, Germany, 11-14 November 2009, (20091111), pages 1 - 6, XP055280423 |
| OPPOSITION | - D29: Patentee’s letter dd. 29.03.2021 |
| OPPOSITION | - D74: Board of Appeal decision in T2156/21 relating to EP2932970 18 December 2023 |
| OPPOSITION | - D79: Preliminary opinion dated 21 September 2023 in T2156/21 for EP2 932 970 |
| OPPOSITION | - D80: Patient Information Leaflet for Isentress (raltegravir) tablets |
| OPPOSITION | - D84: Applicants response to communication under Article 94(3) dated 22nd October 2020 |
| OPPOSITION | - Dhhs, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents", Office of AIDS Research Advisory Council (OARAC), (20091201), pages fp - 161, Office of AIDS Research Advisory Council (OARAC), (20160525), XP055275315 |
| OPPOSITION | - Glaxosmithkline, "EPZICOM® abacavir sulfate and lamivudine. Tablets", EPZICOM Product Label, (20080901), pages 1 - 35, EPZICOM Product Label, URL: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9484, (20160615), XP055280818 |
| OPPOSITION | - Glaxosmithkline, "NCT00726336 | GSK1349572 Drug Interaction With Tenofovir", ClinicalTrials.gov, NLM, (20101015), pages 1 - 11, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT00726336?cond=nct00726336&rank=1&tab=history&a=7#version-content-panel, XP093215203 |
| OPPOSITION | - "HIV-1 Integrase Inhibitors An Emerging Clinical Reality", Dayam 2007 integrase inhibitors review-especially promising, doi:10.2165/00126839-200708030-00003 |
| OPPOSITION | - "Isentress : EPAR - Scientific Discussion", European Medicines Agency, (20080114), pages 1 - 51, URL: https://www.ema.europa.eu/en/medicines/human/EPAR/isentress, (20100106), XP007916620 |
| OPPOSITION | - Jagede Oyebisi, Babu John, Di Santo Roberto, Mccoll Damian J., Weber Jan, Quiñones-Mateu Miguel E., "HIV type 1 integrase inhibitors: <mark>From basic research to clinical implications</mark>", AIDS REVIEWS, PERMANYER PUBLICATIONS, BARCELONA, ES, ES , (20080701), vol. 10, no. 3, ISSN 1139-6121, pages 172 - 189, XP093215145 |
| OPPOSITION | - J. Arribas, A. Lazzarin, F. Raffi, A. Rakhmanova, G. Richmond, J. Rockstroh, J. van Lunzen, B. Young, S. Almond, C. Brothers, S. Min, G. Nichols, "THLBB205: Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: rapid and potent antiviral responses in the interim 16 week- analysis from SPRING-1 (ING112276)", XVIII International Aids Conference; Vienna, Austria, 18-23 July 2011, International AIDS Society, (20110701), XP055275419 |
| OPPOSITION | - Jay Lalezari, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Julie Borland, Richard Stroder, ShuguangChen, Yu Lou, Mark Underwood, Tamio Fujiwara, Stephen Piscitelli, Sherene Min, "Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol", 5IAS 2009 – 5th Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town South Africa, Cape Town South Africa , (20090719), pages 1 - 15, XP055280561 |
| OPPOSITION | - Jay Lalezari, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Julie Borland, Richard Stroder, ShuguangChen, Yu Lou, Mark Underwood, Tamio Fujiwara, Stephen Piscitelli, Sherene Min, "Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol", IAS 2009 - 5th Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town South Africa, Cape Town South Africa , (20090719), pages 1 - 15, XP055280561 |
| OPPOSITION | - Jules Levin, Mark Underwood, Brian Johns, Akihiko Sato, Tamio Fujiwara, William Spreen, "S/GSK1349572: A Next Generation Integrase Inhibitor with activity against Integrase Inhibitor-Resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy", Conference Reports for NATAP, (20090717), XP055280505 |
| OPPOSITION | - Levin Jules, Jose Arribas, Adriano Lazzarin, Francois Raffi, Aza Rakhmanova, Gary Richmond, Jurgen Rockstroh, Jan Van Lunzen, Ben Young, Steve Almond, Cindy Brothers, Sherene Min, Garrett Nichols, "Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276)", AIDS 2010 18th International AIDS Conference (IAC); Vienna, Austria, NATAP, (20100718), pages 1 - 6, XP093216578 |
| OPPOSITION | - Levin, Jules; Jurgen Rockstroh, Franco Fehzarta, Franco Maggiolo, Federico Pulido, Hans-Jürgen Stellbrink, Olga Tsybakova, Patrick Yeni, Steve Almond, Cindy Brothers, Ivy Song, Sherene Min on behalf of the extended SPRING-1 team, "Once-Daily S/GSK1349572 Combination Therapy in Antiretroviral-Naïve Adults: Rapod and Potent 24-Week Antiviral Responses on SPRING-1 Antiviral Responses", Conference Reports for NATAP: 10th International Congress on Drug Therapy in HIV Infection; Glasgow, UK, NATAP, (20101107), pages 1 - 9, XP093216551 |
| OPPOSITION | - Low Andrea, Muesing, Mark, "Understanding and Inhibiting Integrase in the Treatment of HIV Disease", THE PRN NOTEBOOK, (20061101), vol. 11, no. 3, pages 6 - 11, XP093215568 |
| OPPOSITION | - Miller Michael D. et al, "Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral-Experienced Patients", JOURNAL OF INFECTIOUS DISEASES, (20040301), vol. 189, pages 837 - 846, XP093056156 |
| OPPOSITION | - Miller Michael D, Margot Nicolas, Lu Biao, Zhong Lijie, Chen Shan-Shan, Cheng Andrew, Wulfsohn Michael, "Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral-Experienced Patients", JOURNAL OF INFECTIOUS DISEASES, (20040301), vol. 189, pages 837 - 846, XP093056156 |
| OPPOSITION | - Naeger Lisa K, "204790Orig1s000 MICROBIOLOGY REVIEW(S) ; DIVISION OF ANTIVIRAL PRODUCTS (HFD-530) ADDENDUM VIROLOGY REVIEW", MICROBIOLOGY REVIEW(S), FDA CENTER FOR DRUG EVALUATION AND RESEARCH, (20130710), pages 1 - 139, MICROBIOLOGY REVIEW(S), URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000MicroR.pdf, XP093214448 |
| OPPOSITION | - Reiss Peter, Battegay Manuel, Clumeck Nathan, Et.Al., "European AIDS Clinical Society Guidelines 2009", European AIDS Clinical Society Guidelines 2009, European AIDS Clinical Society (EACS), (20091101), pages 1 - 80, European AIDS Clinical Society Guidelines 2009, URL: https://www.eacsociety.org/media/2009_eacsguidelines-v5-english.pdf, XP093215555 |
| OPPOSITION | - S. Min, Et Al, "Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI)", 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Capetown, South, Capetown, South , (20090719), pages 1 - 7, XP055280921 |
| OPPOSITION | - Cécile L. Tremblay, Martin S. Hirsch, "The basic principles for combination therapy", Cécile L. Tremblay, Martin S. Hirsch, E. D. A. De Clercq and A,-M. I. Vandamme, Combination Therapy of AIDS, Springer Basel AG, (20031127), pages 41 - 51, doi:10.1007/978-3-0348-7869-2_3, ISBN 978-3-0348-9604-7, XP009557638 |
| OPPOSITION | - Cécile L. Tremblay, Martin S. Hirsch, "The basic principles for combination therapy", Combination Therapy of AIDS, Springer Basel AG, (20031127), pages 41 - 51, doi:10.1007/978-3-0348-7869-2_3, ISBN 978-3-0348-9604-7, XP009557638 |
| OPPOSITION | - Galizzi Nadia et al, "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients", International Journal of Antimicrobial Agents, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20200109), vol. 55, no. 3, doi:10.1016/j.ijantimicag.2020.105893, ISSN 0924-8579, XP086083636 |
| OPPOSITION | - Galizzi Nadia; Poli Andrea; Galli Laura; Muccini Camilla; Mastrangelo Andrea; Dell'Acqua Raffaele; Maillard Myriam; Bossolasco Simona; Cinque Paola; Lazzarin Adriano; Castagna Antonella; Gianotti Nicola, "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients", International Journal of Antimicrobial Agents, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20200109), vol. 55, no. 3, doi:10.1016/j.ijantimicag.2020.105893, ISSN 0924-8579, XP086083636 |
| OPPOSITION | - Nadia Galizzi et al., "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIVinfected patients", International journal of antimicrobial agents, (2020), vol. 55, doi:10.1016/j.ijantimicag.2020.105893, page 3, XP086083636 |
| OPPOSITION | - CLERCQ DE E., "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection", Il Farmaco, Elsevier France * Editions Scientifiques et Medicales, FR, FR , (19990101), vol. 54., no. 1-2, doi:10.1016/S0014-827X(98)00103-7, ISSN 0014-827X, pages 26 - 45, XP000885648 |
| OPPOSITION | - Brian A Johns, "Chapter 16 - HIV-1 Integrase Strand Transfer Inhibitors", ANNUAL REPORTS IN MEDICINAL CHEMISTRY, Academic Press, US, US , (20100101), vol. 45, doi:10.1016/S0065-7743(10)45016-2, ISSN 0065-7743, pages 262 - 276, XP009183884 |
| OPPOSITION | - Cahn Pedro et al, "SUPPORTING MATERIAL: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20190112), vol. 393, no. 10167, doi:10.1016/S0140-6736(18)32462-0, ISSN 0140-6736, pages 1 - 7, XP093217736 |
| OPPOSITION | - Cahn Pedro, Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E. Clarke; Chien-Ching Hung; Jürgen K. Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R. Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith; Gemini Study Team, "SUPPORTING MATERIAL: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20190112), vol. 393, no. 10167, doi:10.1016/S0140-6736(18)32462-0, ISSN 0140-6736, pages 1 - 7, XP093217736 |
| OPPOSITION | - Yves Pommier, Allison A. Johnson, Christophe Marchand , "Integrase inhibitors to treat HIV/AIDS.", Nature Reviews. Drug Discovery, Nature Publishing Group, GB, GB , (20050301), vol. 4, no. 3, doi:10.1038/nrd1660, ISSN 1474-1784, pages 236 - 248, XP002364769 |
| OPPOSITION | - Hicks Charles, Gulick Roy m., "Raltegravir: The First HIV Type 1 Integrase Inhibitor", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, US , (20090401), vol. 48, no. 7, doi:10.1086/597290, ISSN 1058-4838, pages 931 - 939, XP093215142 |
| OPPOSITION | - Margaret Chesney, "Adherence to HAART Regimens", AIDS PATIENT CARE AND STDS, MARY ANN LIEBERT, INC. LARCHMONT, NY, (20030401), vol. 17, no. 4, doi:10.1089/108729103321619773, ISSN 1087-2914, pages 169 - 177, XP055280914 |
| OPPOSITION | - Osiyemi Olayemi, De Wit Stéphane, Ajana Faïza, Bisshop Fiona, Portilla Joaquín, Routy Jean Pierre, Wyen Christoph, Ait-Khaled Mounir, Leone Peter, Pappa Keith A, Wang Ruolan, Wright Jonathan, George Nisha, Wynne Brian, Aboud Michael, Van Wyk Jean, Smith Kimberly Y, "Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, US , (20220929), vol. 75, no. 6, doi:10.1093/cid/ciac036, ISSN 1058-4838, pages 975 - 986, XP093217740 |
| OPPOSITION | - Van Wyk Jean et al, "Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, US , vol. 71, no. 8, doi:10.1093/cid/ciz1243, ISSN 1058-4838, pages 1920 - 1929, XP093056160 |
| OPPOSITION | - C. Garrido, Et Al, "New therapeutic strategies for raltegravir", Journal of antimicrobial chemotherapy, OXFORD UNIVERSITY PRESS, GB, GB , (20100201), vol. 65, no. 2, doi:10.1093/jac/dkp447, ISSN 0305-7453, pages 218 - 223, XP055280912 |
| OPPOSITION | - FRANK I, "ONCE-DAILY HAART: TOWARD A NEW TREATMENT PARADIGM", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS,PHILADELPHIA, PA, US, US , (20020901), vol. 31, no. SUPPL. 01, doi:10.1097/00126334-200209011-00003 , ISSN 1525-4135, pages S10 - S15, XP009019626 |
| OPPOSITION | - F. Damond, Et Al, "Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients", AIDS, United States, United States , (20080101), vol. 22, no. 5, doi:10.1097/QAD.0b013e3282f51203, pages 665 - 666, XP055280519 |
| OPPOSITION | - Martin Markowitz, Et Al, "Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. Results of a 48-Week Controlled Study", J Acquir Immune Defic Syndr, (20071001), vol. 46, no. 2, doi:10.1097/QAI.0b013e318157131c, pages 125 - 133, XP055280513 |
| OPPOSITION | - BG Gazzard, "British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008", HIV MEDICINE, BLACKWELL SCIENCE, OXFORD, GB, GB , (20080915), vol. 9, no. 8, doi:10.1111/j.1468-1293.2008.00636.x, ISSN 1464-2662, pages 563 - 608, XP072216384 |
| OPPOSITION | - L. Tricot; E. Teicher; G. Peytavin; D. Zucman; F. Conti; Y. Calmus; B. Barrou; C. Duvivier; C. Fontaine; Y. Welker; C. Billy; P. De Truchis; M. Delahousse; D. Vittecoq; D. Salmon‐Céron, "Safety and Efficacy of Raltegravir in HIV‐Infected Transplant Patients Cotreated with Immunosuppressive Drugs", American journal of transplantation, BLACKWELL MUNKSGAARD, DK, DK , (20090610), vol. 9, no. 8, doi:10.1111/j.1600-6143.2009.02684.x, ISSN 1600-6135, pages 1946 - 1952, XP072339935 |
| OPPOSITION | - S. Min, I. Song, J. Borland, S. Chen, Y. Lou, T. Fujiwara, S. C. Piscitelli, "Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20100101), vol. 54, no. 1, doi:10.1128/AAC.00842-09, ISSN 0066-4804, pages 254 - 258, XP055569478 |
| OPPOSITION | - Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki, Chiaki Wakasa-Morimoto, Kevin W. Brown, Robert Ferris, Scott A. Foster, Richard J. Hazen, Shigeru Miki, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark R. Underwood, Edward P. Garvey, Akihiko Sato, Tamio Fujiwara, "In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20110201), vol. 55, no. 2, doi:10.1128/AAC.01209-10, ISSN 0066-4804, pages 813 - 821, XP002680283 |
| OPPOSITION | - E. P. Garvey, B. A. Johns, M. J. Gartland, S. A. Foster, W. H. Miller, R. G. Ferris, R. J. Hazen, M. R. Underwood, E. E. Boros, J. B. Thompson, J. G. Weatherhead, C. S. Koble, S. H. Allen, L. T. Schaller, R. G. Sherrill, T. Yoshinaga, M. Kobayashi, C. Wakasa-Morimoto, S. Miki, K. Nakahara, T. Noshi, A. Sato, T. Fujiwara, "The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20080301), vol. 52, no. 3, doi:10.1128/AAC.01218-07, ISSN 0066-4804, pages 901 - 908, XP055600300 |
| OPPOSITION | - E. P. Garvey et al, "The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20080301), vol. 52, no. 3, doi:10.1128/AAC.01218-07, ISSN 0066-4804, pages 901 - 908, XP055600300 |
| OPPOSITION | - Boucher Charles A B, Cammack Nick, Schipper Pauline, Schuurman Rob, Rouse Philippa, Wainberg Mark A, Cameron2 Janet M, "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'- Thiacytidine In Vitro Is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (19931001), vol. 37, no. 10, doi:10.1128/aac.37.10.2231 , ISSN 0066-4804, pages 2231 - 2234, XP093056148 |
| OPPOSITION | - Boucher Charles A B et al, "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'- Thiacytidine In Vitro Is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (19931001), vol. 37, no. 10, doi:10.1128/aac.37.10.2231 , ISSN 0066-4804, pages 2231 - 2234, XP093056148 |
| OPPOSITION | - Selleseth Dean W., Talarico Christine L., Miller Teresa, Lutz Michael W., Biron Karen K., Harvey Robert J., "Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20030401), vol. 47, no. 4, doi:10.1128/AAC.47.4.1468-1471.2003, ISSN 0066-4804, pages 1468 - 1471, XP093214432 |
| OPPOSITION | - Turner Dan, Brenner Bluma, Wainberg Mark A., "Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1", Clinical and Vaccine Immunology, American Society for Microbiology, (20031101), vol. 10, no. 6, doi:10.1128/CDLI.10.6.979-981.2003, ISSN 1556-6811, pages 979 - 981, XP093056152 |
| OPPOSITION | - Turner Dan et al, "Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1", Clinical and Vaccine Immunology, American Society for Microbiology, (20031101), vol. 10, no. 6, doi:10.1128/CDLI.10.6.979-981.2003, ISSN 1556-6811, pages 979 - 981, XP093056152 |
| OPPOSITION | - Laskey Sarah B., Siliciano Robert F., "Quantitative evaluation of the antiretroviral efficacy of dolutegravir", JCI Insight, (20161117), vol. 1, no. 19, doi:10.1172/jci.insight.90033, XP093056166 |
| OPPOSITION | - Sarah B. Laskey et al., "Quantitative evaluation of the antiretroviral efficacy of dolutegravir", JCI Insight, (2016), vol. 1, doi:10.1172/jci.insight.90033, page 19, XP093056166 |
| OPPOSITION | - J Rockstroh, Felizarta F, Maggiolo F, Pulido F, Stellbrink Hj, Tsybakova O, Yeni P, Almond S, Brothers C, Song I, Min S, "Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)", Journal of the International AIDS Society, BioMed Central Ltd, London, UK, London, UK , (20101108), vol. 13, doi:10.1186/1758-2652-13-S4-O50, ISSN 1758-2652, pages O50 - O50, XP055582245 |
| OPPOSITION | - Eron J; Livrozet JM; Morlat P; Lazzarin A; Katlama C; Hawkins T; Fujiwara T; Cuffe R; Vavro C; Santiago J; Ait-Khaled M; Min S; Yeo JM, "Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)", Journal of the International AIDS Society, BioMed Central Ltd, London, UK, London, UK , (20101108), vol. 13, no. Suppl 4, doi:10.1186/1758-2652-13-S4-O51, ISSN 1758-2652, page O51, XP021084413 |
| OPPOSITION | - Jürgen Kurt Rockstroh , "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", European Journal of Medical Research, BioMed Central Ltd, London, UK, London, UK , (20091124), vol. 14, no. Suppl 3, doi:10.1186/2047-783X-14-S3-1, ISSN 2047-783X, pages 1 - 3, XP021130215 |
| OPPOSITION | - Patricia Pecora Fulco, Et Al, "Raltegravir-Based HAART Regimen in a Patient with Large B-Cell Lymphoma", The Annals of Pharmacotherapy, (20100201), vol. 44, doi:10.1345/aph.1M370, pages 377 - 382, XP055280525 |
| OPPOSITION | - Nicole Prada, Et Al, "Novel integrase inhibitors for HIV", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20100901), vol. 19, no. 9, doi:10.1517/13543784.2010.501078, ISSN 1354-3784, pages 1087 - 1098, XP055275329 |
| OPPOSITION | - Kumar Princy N; Patel Parul, "Lamivudine for the treatment of HIV.", Expert opinion on drug metabolism & toxicology, Informa Healthcare, UK, UK , (20100101), vol. 6, no. 1, doi:10.1517/17425250903490418, ISSN 1744-7607, pages 105 - 114, XP008166807 |
| OPPOSITION | - Katlama Christine, Murphy Robert, "Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection", Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease., (20090101), doi:10.2147/TCRM.S3137, ISSN 1178-203X, pages 331 - 340, XP093230927 |
| OPPOSITION | - Marchand Christophe, Maddali Kasthuraiah, Metifiot Mathieu, Pommier Yves, "HIV-1 IN Inhibitors: 2010 Update and Perspectives", CURRENT TOPICS IN MEDICINAL CHEMISTRY, Bentham Science Publishers Ltd.HILVERSUM, NL, NL , (20090801), vol. 9, no. 11, doi:10.2174/156802609789630910, ISSN 1568-0266, pages 1016 - 1037, XP093216587 |
| OPPOSITION | - Cahn Pedro, Madero Juan Sierra, Arribas José Ramón, Antinori Andrea, Ortiz Roberto, Clarke Amanda E, Hung Chien-Ching, Rockstroh Jürgen K, Girard Pierre-Marie, Sievers Jörg, Man Choy, Currie Alexander, Underwood Mark, Tenorio Allan R, Pappa Keith, Wynne Brian, Fettiplace Anna, Gartland Martin, Aboud Michael, Smith Kimberly, "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", THE LANCET, vol. 393, doi:dx.doi.org/10.1016/ S0140-6736(18)32462-0, pages 143 - 155, XP093056157 |
| SEARCH | - Anonymous, "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects - Full Text View - ClinicalTrials.gov", NCT00951015, (20090803), URL: https://clinicaltrials.gov/ct2/show/NCT00951015, (20190418), XP055582403 [X] 1-9 * the whole document * [Y] 1-9 |
| SEARCH | - J. LALEZARI ET AL, "Shionogi-GlaxoSmithKline Pharmaceuticals, LLC Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Na?ve HIV-1-Infected Patients: ING111521 Protocol", 5IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, Cape Town South Africa, (20090719), pages 1 - 15, XP055280561 [Y] 1-9 * the whole document * |
| SEARCH | - BEALE K K ET AL, "COMBINATIONS OF REVERSE TRANSCRIPTASE, PROTEASE, AND INTEGRASE INHIBITORS CAN BE SYNERGISTIC IN VITRO AGAINST DRUG-SENSITIVE AND RT INHIBITOR-RESISTANT MOLECULAR CLONES OF HIV-1", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, (20000601), vol. 46, no. 3, doi:10.1016/S0166-3542(00)00083-8, ISSN 0166-3542, pages 223 - 232, XP001027294 [I] 1-9 * abstract * * tables 2,3 * * page 231, column 1, line 4 - line 11 * [Y] 1-9 |
| SEARCH | - A SATO ET AL, "S/GSK1349572 is a potent next-generation HIV integrase inhibitor", HIV MEDICINE, GB, (20091019), vol. 10, no. Suppl. 2, doi:10.1111/j.1468-1293.2009.00792.x, ISSN 1464-2662, pages 92 - 92, XP055582260 [Y] 1-9 * Abstract PE7.1/1 * |
| SEARCH | - J ROCKSTROH ET AL, "Once-daily S/GSK1349572 combination therapy in antiretroviral-na�ve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)", JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, London, UK, (20101108), vol. 13, doi:10.1186/1758-2652-13-S4-O50, ISSN 1758-2652, pages O50 - O50, XP055582245 [PX] 1-9 * abstract * |
